Novo Nordisk said Wednesday it will sell Wegovy at lower prices to uninsured patients and to patients whose insurance doesn’t ...

In this podcast, Motley Fool analyst Karl Thiel joins host Ricky Mulvey to check in on the GLP-1 landscape. They discuss: How ...

The commercial success of the injectable peptide-based weight-loss drugs marketed by Novo Nordisk and Eli Lilly and Company ...

Conclave 2025, Vikrant Shrotriya, Managing Director of Novo Nordisk India, said that a weight loss drug is not a magic pill.

The weight-loss drug market is evolving at a rapid speed, with leading pharma companies including Novo Nordisk and Eli Lilly ...

In an exclusive conversation with Business Today, Camilla Sylvest, Executive Vice President, Commercial Strategy & Corporate ...

Exclusive: Vikrant Shrotriya, Corporate Vice President & Managing Director, Novo Nordisk India ... “is not a magic pill”. Ozempic and other weight-loss drugs like Mounjaro and Wegovy are ...

With the FDA shutting down its key revenue stream, Hims faces a tough road ahead--can it justify its valuation?

Could taking tiny fractions of the normal prescribed dose of a medication offer a brilliant way to benefit from the drug, ...

Martin Makary, President Donald Trump's nominee to run the U.S. FDA, told lawmakers on Thursday he would convene a committee ...

New data from Novo Nordisk’s phase 3 trial of an oral ... The 50 mg oral semaglutide pill achieved a 15.1% weight loss in the phase 3 OASIS study involving patients who were overweight or ...

Novo Nordisk has reiterated its position that it ... was challenged on vaccines, the abortion pill, and FDA staffing decisions at a Senate hearing. EU says Novo Holdings’ $16.5 billion takeover ...